MedPath

To determine the ideal maintenance fluid for critically ill children.

Active, not recruiting
Conditions
Abnormal level of blood mineral,
Registration Number
CTRI/2019/10/021791
Lead Sponsor
Department of Pediatrics
Brief Summary

Hospital acquired acute Hyponatremia is increasingly recognised as the cause of morbidity and mortality in children. It has been attributed primarily to the use of hypotonic intravenous fluids to maintain fluid an electrolyte balance. The use of isotonic fluid (0.9% Normal Saline with 5% Dextrose) is recommended in most circumstances. Hypotonic intravenous fluids containing less than or equal to 0.45% NaCL shouldn’t be used to provide as a routine iv fluid maintenance requirement.

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
All
Target Recruitment
162
Inclusion Criteria

All the children more than 3 months and less than 12 years of age requiring fluid management.

Exclusion Criteria
  • a) Children with age less than 3 months of age and more than 12 years of age.
  • b ) Children who have received more than 72 hours of intravenous fluid.
  • d) Children with Renal Disease ( AKI), Cardiac disease ( CHF) or Pituitary dysfunction , Diabetes mellitus.
  • e) Children with baseline sodium values, < 130 meq/dl and > 145 meq/dl.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Proportion of subjects developing hyponatremia after receiving designated fluid for the specified time.72 hours
Secondary Outcome Measures
NameTimeMethod
1. Change in serum sodium levels from the baseline at 48,72 hours in whom iv fluids are continued.2. Occurence of hyponatremia and hypernatremia.

Trial Locations

Locations (1)

Lok Nayak Hospitals

🇮🇳

Central, DELHI, India

Lok Nayak Hospitals
🇮🇳Central, DELHI, India
Kumar Ratnjeet
Principal investigator
07838695570
krat240@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.